230 related articles for article (PubMed ID: 26429877)
1. Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.
Rao CV; Janakiram NB; Madka V; Devarkonda V; Brewer M; Biddick L; Lightfoot S; Steele VE; Mohammed A
Oncotarget; 2015 Oct; 6(32):33290-305. PubMed ID: 26429877
[TBL] [Abstract][Full Text] [Related]
2. Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression.
Mohammed A; Janakiram NB; Madka V; Brewer M; Ritchie RL; Lightfoot S; Kumar G; Sadeghi M; Patlolla JM; Yamada HY; Cruz-Monserrate Z; May R; Houchen CW; Steele VE; Rao CV
Oncotarget; 2015 Jun; 6(17):15524-39. PubMed ID: 25906749
[TBL] [Abstract][Full Text] [Related]
3. The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model.
Mohammed A; Janakiram NB; Li Q; Madka V; Ely M; Lightfoot S; Crawford H; Steele VE; Rao CV
Cancer Prev Res (Phila); 2010 Nov; 3(11):1417-26. PubMed ID: 21084261
[TBL] [Abstract][Full Text] [Related]
4. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
5. Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib.
Poteet E; Liu D; Liang Z; Van Buren G; Chen C; Yao Q
PLoS One; 2019; 14(3):e0213294. PubMed ID: 30921351
[TBL] [Abstract][Full Text] [Related]
6. Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
Ali S; Banerjee S; Schaffert JM; El-Rayes BF; Philip PA; Sarkar FH
J Cell Biochem; 2010 May; 110(1):171-81. PubMed ID: 20213764
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention.
Mohammed A; Janakiram NB; Li Q; Choi CI; Zhang Y; Steele VE; Rao CV
Cancer Prev Res (Phila); 2011 Dec; 4(12):2015-26. PubMed ID: 21885812
[TBL] [Abstract][Full Text] [Related]
8. Novel di-tertiary-butyl phenylhydrazones as dual cyclooxygenase-2/5-lipoxygenase inhibitors: synthesis, COX/LOX inhibition, molecular modeling, and insights into their cytotoxicities.
Ghatak S; Vyas A; Misra S; O'Brien P; Zambre A; Fresco VM; Markwald RR; Swamy KV; Afrasiabi Z; Choudhury A; Khetmalas M; Padhye S
Bioorg Med Chem Lett; 2014 Jan; 24(1):317-24. PubMed ID: 24295787
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of 5-LOX and COX-2 suppresses esophageal squamous cell carcinoma.
Shi HY; Lv FJ; Zhu ST; Wang QG; Zhang ST
Cancer Lett; 2011 Oct; 309(1):19-26. PubMed ID: 21652147
[TBL] [Abstract][Full Text] [Related]
10. Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors.
Ding X; Zhu C; Qiang H; Zhou X; Zhou G
Biomed Pharmacother; 2011 Oct; 65(7):486-90. PubMed ID: 21993002
[TBL] [Abstract][Full Text] [Related]
11. Anticancer effects of licofelone (ML-3000) in prostate cancer cells.
Narayanan NK; Nargi D; Attur M; Abramson SB; Narayanan BA
Anticancer Res; 2007; 27(4B):2393-402. PubMed ID: 17695530
[TBL] [Abstract][Full Text] [Related]
12. Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase.
Knab LM; Grippo PJ; Bentrem DJ
World J Gastroenterol; 2014 Aug; 20(31):10729-39. PubMed ID: 25152576
[TBL] [Abstract][Full Text] [Related]
13. Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells.
Misra S; Ghatak S; Patil N; Dandawate P; Ambike V; Adsule S; Unni D; Venkateswara Swamy K; Padhye S
Bioorg Med Chem; 2013 May; 21(9):2551-9. PubMed ID: 23517721
[TBL] [Abstract][Full Text] [Related]
14. Characterization of spirostanol glycosides and furostanol glycosides from anemarrhenae rhizoma as dual targeted inhibitors of 5-lipoxygenase and Cyclooxygenase-2 by employing a combination of affinity ultrafiltration and HPLC/MS.
Xie L; Lee DY; Shang Y; Cao X; Wang S; Liao J; Zhang T; Dai R
Phytomedicine; 2020 Oct; 77():153284. PubMed ID: 32707371
[TBL] [Abstract][Full Text] [Related]
15. The different inhibitory effects of Huang-Lian-Jie-Du-Tang on cyclooxygenase 2 and 5-lipoxygenase.
Li L; Zeng H; Shan L; Yuan X; Li Y; Liu R; Zhang W
J Ethnopharmacol; 2012 Sep; 143(2):732-9. PubMed ID: 22884869
[TBL] [Abstract][Full Text] [Related]
16. Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.
Kirane A; Toombs JE; Ostapoff K; Carbon JG; Zaknoen S; Braunfeld J; Schwarz RE; Burrows FJ; Brekken RA
Clin Cancer Res; 2012 Sep; 18(18):5031-42. PubMed ID: 22829202
[TBL] [Abstract][Full Text] [Related]
17. Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
Li N; Li H; Su F; Li J; Ma X; Gong P
Int J Clin Exp Pathol; 2015; 8(8):9010-20. PubMed ID: 26464643
[TBL] [Abstract][Full Text] [Related]
18. Endogenous n-3 polyunsaturated fatty acids delay progression of pancreatic ductal adenocarcinoma in Fat-1-p48(Cre/+)-LSL-Kras(G12D/+) mice.
Mohammed A; Janakiram NB; Brewer M; Duff A; Lightfoot S; Brush RS; Anderson RE; Rao CV
Neoplasia; 2012 Dec; 14(12):1249-59. PubMed ID: 23308056
[TBL] [Abstract][Full Text] [Related]
19. Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.
Conradt L; Godl K; Schaab C; Tebbe A; Eser S; Diersch S; Michalski CW; Kleeff J; Schnieke A; Schmid RM; Saur D; Schneider G
Neoplasia; 2011 Nov; 13(11):1026-34. PubMed ID: 22131878
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
